Back to top
more

Voyager Therapeutics (VYGR)

(Delayed Data from NSDQ)

$8.43 USD

8.43
529,986

-0.20 (-2.32%)

Updated May 17, 2024 04:00 PM ET

After-Market: $8.44 +0.01 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 54.55% and 88.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 21.48% and 85.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 26.17% and 10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.

Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat

Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.

Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates

Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.

Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates

Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.

Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates

Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.

Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates

Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.

Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates

Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.

Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short

Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.

New Strong Buy Stocks for May 1st

EC, SKX, BVN, VYGR and WU have been added to the Zacks Rank #1 (Strong Buy) List on May 1, 2023.

Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More

Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 13.56% and 142.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 1,860% and 51.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Lumos Pharma (LUMO) Reports Q1 Loss, Tops Revenue Estimates

Lumos (LUMO) delivered earnings and revenue surprises of 20.54% and 126.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.41% and 0.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -5.88% and 78.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 20% and 6.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 21.57% and 9.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?